CliffBio
biologic

Humira

adalimumab

Loss of exclusivityApril 2029projected — 12-year biologic exclusivity estimate
CompanyAbbVie Inc. →View the full company profile on CliffBio

Drug detail

Brand nameHumira
Active ingredientadalimumab
Strength20MG/0.2ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalApril 2017
Marketing statusRx

More from AbbVie Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Humira patent cliff — loss of exclusivity April 2029 | CliffBio